Unlocking the Future of Radiopharmaceutical Therapy
In an exciting upcoming webinar, attendees will uncover the best practices for selecting and validating preclinical tumor models pivotal in understanding target biology and translational outcomes. This session will feature distinguished speakers who will delve into critical radiochemistry elements essential for isotope labeling and chelator techniques, aimed at generating reliable data. Participants will learn about optimizing study designs focusing on biodistribution, dosimetry, and efficacy, ensuring informed clinical decisions.
Identifying Key Factors for Successful Radioligand Therapy
The rapid advancement in radioligand therapy brings a wealth of opportunities, yet the journey is often hindered by challenges like selecting appropriate preclinical models and strategies. The webinar will offer insights on how adopting informed and strategic decisions early in research can minimize risks, validate therapeutic targets, and facilitate smoother transitions from discovery to clinical applications.
Webinar Highlights and Learning Outcomes
This engaging session is tailored for researchers, drug developers, and translational scientists with a keen interest in radioligand therapy and targeted therapies. The topics to be explored include:
- Best practices for choosing tumor models that accurately reflect biology and target expression.
- Important considerations in radiochemistry, including isotope selection and labeling approaches.
- Strategies for designing preclinical studies that effectively address critical translational queries.
- Ways to produce decision-ready data that supports clinical applications.
- A glioblastoma case study demonstrating how advanced imaging techniques involving [¹??Lu]FAP-2886 can identify FAP targeting and therapeutic potential in preclinical models.
Join Us for Expert Insights
Don’t miss the opportunity to hear from industry experts, including professionals from Perceptive, who will lead a discussion on the transformative impact of imaging-based evaluations in changing the course of radiopharmaceutical therapy development. Their insights will help reduce risks and expedite the journey of promising therapies to those who need them the most.
Event Details
This live webinar will occur at 9 AM EST, featuring Mike Batey, Senior Director, SMS Discovery, along with Dr. Julian Goggi, Director of Discovery Research. With a focus on collaborative learning, this session invites participants to engage directly with thought leaders in the field.
About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., stands out as a premier source for educational webinars and digital resources serving the global life sciences, food, healthcare, and medical device sectors. Each year, thousands in the industry, spanning pharmaceuticals, biotechnology, and private research institutions, rely on Xtalks to access cutting-edge content. Xtalks plays a crucial role in helping professionals keep updated on industry trends, regulations, and career opportunities.
To explore more about Xtalks, visit their website directly for insights and educational opportunities tailored to enhance professional growth within the life sciences community.
Frequently Asked Questions
What is the focus of the webinar?
The webinar will concentrate on selecting and validating preclinical tumor models relevant to radiopharmaceutical therapy, along with radiochemistry considerations.
Who are the speakers for the session?
Featured speakers include industry experts from Perceptive, including Mike Batey and Dr. Julian Goggi.
When is the webinar scheduled?
The webinar will take place at 9 AM EST, providing an excellent opportunity for live participation and Q&A.
How can attendees benefit from this webinar?
Participants will gain valuable insights into best practices for preclinical study designs and understanding critical translational questions in radioligand therapy.
Is there a registration fee for the webinar?
The webinar is free of charge, intended for researchers and professionals keen to learn about advancements in radiopharmaceutical therapy.
